13F HOLDINGS REPORT
Foresite Capital Management IV, LLC
Quarter ended Q2 2024 · Filed August 13, 2024 · Accession 0001104659-24-088863
Total Value
$148.8M
Positions
4
Other Managers
0
Confidential Omitted
No
Holdings (4)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Pharvaris N.V. | PHVS | 4,293,854 | $80.7M | 54.23% |
| 2 | Kura Oncology, Inc. | KURA | 1,849,947 | $38.1M | 25.59% |
| 3 | Syndax Pharmaceuticals, Inc. | SNDX | 875,000 | $18.0M | 12.07% |
| 4 | Lyell Immunopharma, Inc. | LYEL | 8,325,000 | $12.1M | 8.11% |